Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: Final results of a dose-finding and efficacy study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 4, 2001, Pages 328-335

  Viens, Patrice ^a   Roché, Henri ^b   Kerbrat, Pierre ^c   Fumoleau, Pierre ^d   Guastalla, Jean Paul ^e   Delozier, Thierry ^f  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e CENTRE LÉON BÉRARD   (France)

^f CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Docetaxel; Dose finding; Efficacy; Epirubicin; MBC

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; DOCETAXEL; EPIRUBICIN;

ADULT; AGED; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS;

EID: 0034909446     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200108000-00002     Document Type: Article

References (44)

1. Adriamycin in breast cancer: An overview of studies
2. Experience of the ECOG with doxorubicin as a simple agent in patients with previously untreated breast cancer
3. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients
4. Ten year results of the French trial comparing adriamycin, vincristine, 5-fluorouracil and cyclophosphamide to standard CMF as adjuvant therapy for node-positive breast cancer
5. Doxorubicin-containing regimens for the treatment of stage II breast cancer. The NSABP experience
6. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive node breast cancer patients with tamoxifen non responsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
7. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes
8. Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin and cyclophosphamide in premenopausal women with axillary nodepositive operable breast cancer: Results of a randomized trial
9. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
10. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin
11. Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial
12. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the EORTC-CSG
13. Paclitaxel in metastatic breast cancer: A trial of two doses by 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines
14. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
15. Three hour Taxol infusion as initial and as salvage chemotherapy of metastatic breast cancer
16. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
17. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
18. Doxorubicin plus paclitaxel in advanced breast cancer
19. Metastatic breast cancer: Experience with the combination paclitaxel plus epirubicin
20. Paclitaxel plus epirubicin in advanced breast cancer
21. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
22. Reporting results of cancer treatment
23. Non parametric estimation from incomplete observations
24. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
25. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study
26. Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer. A phase I/II study of the National Cancer Institute of Canada-Clinical Trials Group
27. First line epirubicin (epi) and taxotere (txt) in advanced breast cancer: A phase I study
28. A phase II pilot study of docetaxel and epirubicin in metastatic breast cancer: Preliminary results
29. Phase II evaluation of docetaxel and epidoxorubicin + G-CSF in primary and advanced breast cancer
30. Final results of a phase II study of taxotere (T), doxorubicin (A) and cyclophosphamide (C) (TAC) as 1st line CT in metastatic breast cancer patients
31. Phase II trial of doxorubicin and docetaxel (Taxotere) plus granulocyte-colony stimulating factor (G-CSF) in metastatic breast cancer (MBC): An Eastern Cooperative Oncology Group Study (E1196)
32. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial
33. Conventional versus high-dose epidoxorubicin as single agent in advanced breast cancer
34. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial
35. 2) in the FEC regimen significantly increases responses rates. An international randomised phase III study in metastatic breast cancer
36. Final results of a randomized trial comparing three epirubicin-based regimens as first line chemotherapy in metastatic breast cancer (MBC) patients (Pts)
37. Risk factors for doxorubicin-induced congestive heart failure
38. Adriamycin cardiotoxicity: A survey of 1273 patients
39. Doxorubicin/taxane combinations: Cardiac toxicity and pharmacokinetics
40. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors
41. Evaluation of the cardiotoxicity of anthracyclines associated to Taxol with the model of isolated perfused rat heart
42. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients
43. The pharmacokinetics of epirubicin and docetaxel in combination in rats
44. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomised study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group